Kazi Hasan Takes the Helm as Chief Financial Officer
February 3, 2025 - 20:00
WHITE PLAINS, N.Y., February 3, 2025—In a significant leadership change, OPAL Fuels Inc. has announced the appointment of Kazi Hasan as its new Chief Financial Officer, effective immediately. Hasan steps into the role following the tenure of Scott Contino, who has been serving as the interim CFO since October 2023. Contino will maintain his position as Chief Financial Officer for Fortistar, the company’s sponsor.
Kazi Hasan brings a wealth of financial expertise and leadership experience to OPAL Fuels. His appointment is seen as a strategic move to enhance the company's financial operations and support its growth initiatives. The transition comes at a pivotal time for OPAL Fuels as it continues to expand its footprint in the renewable energy sector.
The company expressed confidence in Hasan's capabilities to drive financial strategy and operational efficiency. As OPAL Fuels embarks on its next chapter, stakeholders are optimistic about the direction under Hasan’s leadership.
MORE NEWS
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...